Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Jan 1;28(1):35-42.
doi: 10.1200/JCO.2009.23.2272. Epub 2009 Nov 23.
Ariane Dunant, Jean-Pierre Pignon, Bengt Bergman, Mariusz Chabowski, Dominique Grunenwald, Miroslaw Kozlowski, Cécile Le Péchoux, Robert Pirker, Maria-Izabel Sathler Pinel, Michèle Tarayre, Thierry Le Chevalier
Affiliations
- PMID: 19933916
- DOI: 10.1200/JCO.2009.23.2272
Randomized Controlled Trial
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer
Rodrigo Arriagada et al. J Clin Oncol. 2010.
Abstract
PURPOSE Based on 5-year or shorter-term follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non-small-cell lung cancer (NSCLC). We evaluated the results of the International Adjuvant Lung Cancer Trial study with three additional years of follow-up. PATIENTS AND METHODS Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. Cox models were used to evaluate treatment effect according to follow-up duration. Results The trial included 1,867 patients with a median follow-up of 7.5 years. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.02; P = .10) and on disease-free survival (HR, 0.88; 95% CI, 0.78 to 0.98; P = .02). However, there was a significant difference between the results of overall survival before and after 5 years of follow-up (HR, 0.86; 95% CI, 0.76 to 0.97; P = .01 v HR, 1.45; 95% CI, 1.02 to 2.07; P = .04) with P = .006 for interaction. Similar results were observed for disease-free survival. The analysis of non-lung cancer deaths for the whole period showed an HR of 1.34 (95% CI, 0.99 to 1.81; P = .06). CONCLUSION These results confirm the significant efficacy of adjuvant chemotherapy at 5 years. The difference in results beyond 5 years of follow-up underscores the need for the long-term follow-up of other adjuvant lung cancer trials and for a better identification of patients deriving long-term benefit from adjuvant chemotherapy.
Similar articles
- Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, Spiro S, Shepherd FA. Früh M, et al. J Clin Oncol. 2008 Jul 20;26(21):3573-81. doi: 10.1200/JCO.2008.16.2727. J Clin Oncol. 2008. PMID: 18640938 - Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG. Waller D, et al. Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82. doi: 10.1016/j.ejcts.2004.03.041. Eur J Cardiothorac Surg. 2004. PMID: 15200998 Clinical Trial. - Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E. Filipits M, et al. J Clin Oncol. 2007 Jul 1;25(19):2735-40. doi: 10.1200/JCO.2006.08.2867. J Clin Oncol. 2007. PMID: 17602078 Clinical Trial. - Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
Sasidharan R, Gibbs D, Sullivan R, Simpson A, Perez D, Christmas T, McKeage M. Sasidharan R, et al. N Z Med J. 2006 Nov 17;119(1245):U2310. N Z Med J. 2006. PMID: 17146485 Review. - Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
Geiger S, Schlemmer M, Heinemann V, Stemmler HJ. Geiger S, et al. Anticancer Drugs. 2010 Oct;21(9):799-804. doi: 10.1097/CAD.0b013e32833dbbfe. Anticancer Drugs. 2010. PMID: 20679887 Review.
Cited by
- A standing platform for cancer drug development using ctDNA-based evidence of recurrence.
Medford AJ, Carmeli AB, Ritchie A, Wagle N, Garraway L, Lander ES, Parikh A. Medford AJ, et al. Nat Rev Cancer. 2024 Sep 30. doi: 10.1038/s41568-024-00742-2. Online ahead of print. Nat Rev Cancer. 2024. PMID: 39349822 Review. - Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, Carnevale Schianca A, Trillo Aliaga P, Del Signore E, Spitaleri G, Passaro A, de Marinis F. Fuorivia V, et al. Curr Oncol. 2024 Aug 30;31(9):5121-5139. doi: 10.3390/curroncol31090379. Curr Oncol. 2024. PMID: 39330007 Free PMC article. Review. - The Role of Adjuvant Chemotherapy in pN1 (IIB/IIIA) NSCLC Patients Who Undergo Pneumonectomy: Is It Still Justified in the Modern Era?
Mazzella A, Orlandi R, Maiorca S, Uslenghi C, Maisonneuve P, Casiraghi M, Bertolaccini L, Spaggiari L. Mazzella A, et al. Cancers (Basel). 2024 Aug 31;16(17):3041. doi: 10.3390/cancers16173041. Cancers (Basel). 2024. PMID: 39272899 Free PMC article. - T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L, Xu Z, Ma T, Wang C, Wei P, Xiao B, Zhang H, Che N, Liu Z, Han Y. Yi L, et al. Cancer Immunol Immunother. 2024 Apr 15;73(6):99. doi: 10.1007/s00262-024-03687-5. Cancer Immunol Immunother. 2024. PMID: 38619623 Free PMC article. - Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers.
Stewart DJ, Cole K, Bosse D, Brule S, Fergusson D, Ramsay T. Stewart DJ, et al. Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122. Curr Oncol. 2024. PMID: 38534955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical